Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancerShunichi Sugawara, Kazuhiko Nakagawa, K.H. Lee et al.|Annals of Oncology|2021Cited by 202
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)Takashi Seto, Kazuhiko Nakagawa, Kaname Nosaki et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 50
Distinct clinicopathological phenotype of hepatocellular carcinoma with ethoxybenzyl-magnetic resonance imaging hyperintensity: association with gene expression signatureTomoya Miura, Minoru Tanabe, Daisuke Ban et al.|The American Journal of Surgery|2015Cited by 27
First‐line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non‐squamous non‐small cell lung cancer: Updated survival analysis of the <scp>ONO</scp>‐4538‐52/<scp>TASUKI</scp>‐52 randomized controlled trialHye Ryun Kim, Kazuhiko Nakagawa, Shunichi Sugawara et al.|Cancer Medicine|2023Cited by 26
Age-related clinicopathologic and molecular features of patients receiving curative hepatectomy for hepatocellular carcinomaEriko Katsuta, Shigeki Arii, Shinji Tanaka et al.|The American Journal of Surgery|2014Cited by 23